BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China and the United States. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and BAT1706 to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. BeiGene, Ltd. has a strategic collaboration with Shoreline Biosciences, Inc. to develop and commercialize a portfolio of NK-based cell therapeutics. The company was incorporated in 2010 and is headquartered in Beijing, the People's Republic of China.
IPO Year: 2016
Exchange: NASDAQ
Website: beigene.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/3/2024 | $300.00 | Overweight | Morgan Stanley |
| 9/18/2024 | $288.00 | Mkt Outperform | JMP Securities |
| 2/6/2024 | $185.00 | Overweight | JP Morgan |
| 9/12/2023 | $259.00 | Outperform | Macquarie |
| 8/17/2023 | $287.00 | Buy | Jefferies |
| 7/17/2023 | $275.00 | Buy | Citigroup |
| 6/30/2023 | $335.00 → $196.00 | Outperform → Mkt Perform | Bernstein |
| 1/12/2023 | $308.00 | Buy | Daiwa Securities |
| 10/13/2022 | $205.00 | Neutral → Buy | Guggenheim |
| 10/13/2022 | $177.00 → $200.00 | Mkt Perform → Outperform | SVB Leerink |
4 - BeiGene, Ltd. (0001651308) (Issuer)
4 - BeiGene, Ltd. (0001651308) (Issuer)
4 - BeiGene, Ltd. (0001651308) (Issuer)
4 - BeiGene, Ltd. (0001651308) (Issuer)
4 - BeiGene, Ltd. (0001651308) (Issuer)
4 - BeiGene, Ltd. (0001651308) (Issuer)
4 - BeiGene, Ltd. (0001651308) (Issuer)
4 - BeiGene, Ltd. (0001651308) (Issuer)
3 - BeiGene, Ltd. (0001651308) (Issuer)
4 - BeiGene, Ltd. (0001651308) (Issuer)
SC 13D/A - BeiGene, Ltd. (0001651308) (Subject)
SC 13D/A - BeiGene, Ltd. (0001651308) (Subject)
SC 13D/A - BeiGene, Ltd. (0001651308) (Filed by)
SC 13G/A - BeiGene, Ltd. (0001651308) (Subject)
SC 13G/A - BeiGene, Ltd. (0001651308) (Subject)
SC 13D/A - BeiGene, Ltd. (0001651308) (Subject)
SC 13D/A - BeiGene, Ltd. (0001651308) (Subject)
SC 13G/A - BeiGene, Ltd. (0001651308) (Subject)
SC 13G/A - BeiGene, Ltd. (0001651308) (Subject)
SC 13G/A - BeiGene, Ltd. (0001651308) (Subject)
8-K - BeiGene, Ltd. (0001651308) (Filer)
8-K - BeiGene, Ltd. (0001651308) (Filer)
144 - BeiGene, Ltd. (0001651308) (Subject)
144 - BeiGene, Ltd. (0001651308) (Subject)
144 - BeiGene, Ltd. (0001651308) (Subject)
8-K - BeiGene, Ltd. (0001651308) (Filer)
8-K - BeiGene, Ltd. (0001651308) (Filer)
SCHEDULE 13D/A - BeiGene, Ltd. (0001651308) (Filed by)
8-K - BeiGene, Ltd. (0001651308) (Filer)
144 - BeiGene, Ltd. (0001651308) (Subject)
Morgan Stanley resumed coverage of BeiGene with a rating of Overweight and set a new price target of $300.00
JMP Securities initiated coverage of BeiGene with a rating of Mkt Outperform and set a new price target of $288.00
JP Morgan resumed coverage of BeiGene with a rating of Overweight and set a new price target of $185.00
Macquarie initiated coverage of BeiGene with a rating of Outperform and set a new price target of $259.00
Jefferies initiated coverage of BeiGene with a rating of Buy and set a new price target of $287.00
Citigroup initiated coverage of BeiGene with a rating of Buy and set a new price target of $275.00
Bernstein downgraded BeiGene from Outperform to Mkt Perform and set a new price target of $196.00 from $335.00 previously
Daiwa Securities initiated coverage of BeiGene with a rating of Buy and set a new price target of $308.00
Guggenheim upgraded BeiGene from Neutral to Buy and set a new price target of $205.00
SVB Leerink upgraded BeiGene from Mkt Perform to Outperform and set a new price target of $200.00 from $177.00 previously
BeiGene acquires exclusive option for global license to investigational antibody drug conjugate; DualityBio to continue preclinical research activities and support Investigational New Drug filing BeiGene (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global biotechnology company, and DualityBio, a next-generation ADC company, today announced an agreement for BeiGene to acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC therapy for patients with select solid tumors. "With one of the industry's leading global oncology research teams, we are investing in highly impactful therapeutic modalities such as ADCs that complement our dynam
Final ALPINE Progression-Free Survival (PFS) results simultaneously published in The New England Journal of Medicine and presented at late-breaking session at 64th American Society of Hematology Annual Meeting BRUKINSA demonstrated superiority to IMBRUVICA in both PFS and Overall Response Rate with fewer cardiac events BeiGene (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))) a global biotechnology company, today presented the final progression-free survival (PFS) analysis of the ALPINE trial demonstrating superior efficacy and a favorable cardiac safety profile for patients receiving BRUKINSA® as compared to IMBRUVICA® in a global phase 3 trial in patients with relapsed/refractory (R/R) chronic
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160))), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that it will host an investor conference call and webcast on Wednesday, August 25, 2021, at 9:30 a.m. ET to discuss the Company's early development pipeline and research. A live webcast of the conference call can be accessed from the investors section of BeiGene's website at http://ir.beigene.com or http://hkexir.beigene.com. An archived replay will be available after the event for 90 days. About BeiGene BeiGene is a global, science-driven biotechnology company
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that its partner, BeiGene, Ltd., has dosed the first patient in South Korea in a pivotal, single-arm clinical trial of zanidatamab (formerly ZW25) monotherapy in patients with advanced or metastatic HER2-amplified biliary tract cancer (BTC). Zymeworks will receive a US$10 million payment under its collaboration with BeiGene as a result of the achievement of this development milestone. “Patients with biliary tract cancer generally have a poor prognosis and few treatment options,” said Diana Hausman, M.D., C
THOUSAND OAKS, Calif., Nov. 30, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced several upcoming data presentations from its oncology and hematology pipeline and marketed product portfolio at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, Dec. 5-8, 2020. Amgen will present updated data from its bispecific T cell engager (BiTE®) portfolio in two oral presentations. Data include the first safety and efficacy findings from the ongoing Phase 1 dose escalation study of AMG 701, an investigational half-life extended BiTE immuno-oncology therapy targeting B-cell maturation antigen (BCMA), in patients with heavily pre-treated relapsed/refractory multiple myel
Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to the CEO through April 2025 to ensure a seamless transition of his current role and assist with strategic initiatives underway within the company.
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company, today announced the appointment of Shalini Sharp to its Board of Directors and as a member of the Board's Audit Committee, effective September 27, 2024. "We are fortunate to welcome Shalini to the Board of Directors at this pivotal moment of growth," said John V. Oyler, Co-Founder, Chairman and CEO of BeiGene. "The Board is looking forward to collaborating with Shalini, whose extensive experience in leading innovative global pharmaceutical companies will be invaluable as we enter new markets, advance our pipeline of groundbreaking cancer therapies, and embark on a transformative growth phase. Her financial
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company, today announced the appointment of Matt Shaulis as General Manager of North America, effective September 25. "We are excited to welcome Matt, who brings a wealth of global pharmaceutical experience, including leading the commercialization of blockbuster franchises at multiple multinational companies," said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. "Matt's management will be pivotal as we continue our leadership in hematology with BRUKINSA and replicate that success in solid tumors, with a deep and exciting pipeline of innovative therapies." Mr. Shaulis is a global commercial executive with ov
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the Company through August to support the transition. "We are thrilled to welcome Aaron amid a transformational year for BeiGene as we became a top 15 global oncology innovator by revenue with sustained progress to profitability and one of the most prolific and innovative pipelines in our industry including a plan to have at least 10 new molecular entities this year. Aaron's financial leadership and impr
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global biotechnology company, today announced that Olivier Brandicourt, M.D. has been appointed to its Board of Directors. Dr. Brandicourt will join the audit committee of the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240123611725/en/Olivier Brandicourt, M.D. (Photo: Business Wire) Dr. Brandicourt replaces Thomas Malley, who has served on the Board since 2016. "Dr. Brandicourt brings a wealth of global experience as we expand the perspective of BeiGene's Board of Directors to include deep expertise in leading multinational growth companies, spearheading lau
Pryor will spearhead BeiGene's efforts to pair global health equity with diversity and inclusion BeiGene (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global biotechnology company, today announced the appointment of Julius Pryor III as its first Global Head of Diversity and Health Equity, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230330005198/en/Julius Pryor III (Photo: Business Wire) Mr. Pryor has more than 30 years of experience in Diversity, Equity, Inclusion & Belonging (DEI&B) efforts, having successfully built transformational DEI&B programs for biotechnology companies, as well as global consumer
BeiGene (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology biotechnology company focused on developing and commercializing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the appointment of Chan Lee as General Counsel, effective July 18, 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220713005323/en/Chan Lee, General Counsel, BeiGene (Photo: Business Wire) Mr. Lee joins BeiGene from Sanofi and will bring his significant expertise leading legal functions in the biopharma industry to overseeing legal, compliance, intellectual property and related m
-- Jane Huang, M.D., appointed as independent director -- -- Sanjay Trehan joins as SVP of Business Development -- -- Gretchen Bain, Ph.D., promoted to SVP of Biology -- 858 Therapeutics today announced the strengthening of its board of directors and leadership team in preparation for its next stage of growth. To support the advancement of 858 Therapeutics' portfolio of small molecule therapeutics directed against oncology targets, the company has named Jane Huang, M.D., as an independent director on the company's Board. In addition, 858 Therapeutics has appointed Sanjay Trehan as SVP of Business Development and has promoted Gretchen Bain, Ph.D., to SVP of Biology. The company debuted i
Industry Leaders Lend Scientific and Clinical Expertise to Several Board Committees BeiGene (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the appointment of Margaret Dugan, M.D., and Alessandro Riva, M.D., to its Board of Directors. Dr. Dugan will join the scientific advisory committee and Dr. Riva will join the nominating and corporate governance, and scientific advisory committees of the board. In addition, Jing-Shyh (Sam) Su will be stepping down from BeiGene's board of directors after serving for almost fo
NOVATO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 29, 2021. Dr. Sanders, an experienced veteran of the biopharma industry, will serve as an independent director. "Dr. Sanders' established experience in global clinical development and especially with new technologies will be instrumental as we further advance our ongoing clinical trials and continue to expand our rare disease pipeline of novel therapeut
Positive opinion for first-line treatment of extensive-stage small cell lung cancer based on results of RATIONALE-312 study demonstrating statistically significant overall survival benefit for TEVIMBRA in combination with chemotherapy BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA® (tislelizumab), in combination with etoposide and platinum chemotherapy, as a first-line treatment for adult patients with extensive-stage small cell lu
New indication based on results from a global Phase 3 trial demonstrating TEVIMBRA plus chemotherapy significantly improved overall survival for patients with advanced gastric cancers Second FDA approval for TEVIMBRA in 2024 BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors e
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., announced it will change its Nasdaq ticker symbol to "ONC" on January 2, 2025, reflecting its long-standing commitment to delivering innovative oncology medicines globally. "As we enter our 15th year, changing our ticker to ONC reflects our unwavering commitment to leadership in oncology and mission to deliver transformative medicines to cancer patients worldwide," said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. "This milestone inspires pride in all we have accomplished and fuels our excitement for the future as we advance our innovative h
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it has entered into a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. ("CSPC") for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. SYH2039 targets solid tumors that have a mutation called MTAP deletion, which is estimated to be present in approximately 15 percent of all cancer types with the most common including glioblastoma, pancreatic cancer and non-small cell lung cancer. "With one of the most dynamic solid tumor portfolios in the
5-year follow-up from SEQUOIA study demonstrated treatment with BRUKINSA reduced the risk of progression or death by 71% compared to bendamustine-rituximab in patients with treatment-naïve CLL, further solidifying its position as the leader in new patient starts in both frontline and relapsed/refractory (R/R) CLL with the broadest label of any BTK inhibitor At a median follow-up of 1.5 years, promising data from the 320 mg expansion cohort of phase 1/1b study shows no progression in patients with treatment-naïve CLL treated with sonrotoclax, a next-generation BCL2 inhibitor, in combination with BRUKINSA highlighting the potential of this fixed-duration, oral-only combination as a best-in-
About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely to be efficacious Campaign highlights national treatment guidelines supporting targeted therapies rather than chemotherapy for improved CLL outcomes BeiGene and CLL Society launch partnership during the American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 7-10 in San Diego, California BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced its new partner
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it will host an investor webcast on December 16, 2024 at 8:30 am EST. The Company's R&D leadership team will provide an update on BeiGene's innovative portfolio and pipeline, focusing on key presentations at the American Society of Hematology Meeting (ASH) and the San Antonio Breast Cancer Symposium. The live webcast of this event can be accessed from the investors section of BeiGene's website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. An archived replay will be available for 90 days following th
New indications based on two Phase 3 studies demonstrating statistically significant overall survival benefit for patients treated with TEVIMBRA in combination with chemotherapy BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines, today announced that the European Commission has approved TEVIMBRA® (tislelizumab) in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. "Patients diagnosed with advanced gastric and esophageal cancers confront median survival times measured in months, not years—hi
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it will participate in fireside chats at two upcoming investor conferences: Citizens JMP Hematology and Oncology Summit on Monday, December 2 at 1:00 p.m. ET; and Citi's Global Healthcare Conference on Thursday, December 5 at 9:30 a.m. ET The live webcasts of these events can be accessed from the investors section of BeiGene's website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. An archived replay will be available for 90 days following the event. About BeiGene BeiGene, which plans to ch
Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to the CEO through April 2025 to ensure a seamless transition of his current role and assist with strategic initiatives underway within the company.